# Evolus Inc. (EOLS) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $7.37, market value $487 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Evolus Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.5×**. Each dollar of revenue is priced at 1.5×.
- **Free-cash-flow yield: -3.8%** (5-yr avg -10.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 66.7%**. Evolus Inc. keeps 66.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -5.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -17.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: 223.5%**. A 223.5% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: -21.3%**. Return on all capital, debt included, is -21.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -15.2%**. Each dollar of assets produces -15.2% of profit.

## Growth
- **Revenue growth (1 yr): 11.6%** (3-yr 26.0%/yr, 5-yr 39.4%/yr). Revenue grew 11.6% over the last year, against 39.4% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 1.2%**. Earnings per share rose 1.2%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. Evolus Inc. holds more cash than debt.
- **Current ratio: 1.90** (quick 1.90). Current assets cover the next year's liabilities 1.90 times.
- **Altman Z-score: 2.23**. A Z-score of 2.23 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Evolus Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 10.8%** (YTD 7.7%, 3-mo 18.3%). The shares are up 10.8% over twelve months including dividends.
- **From 52-week high: -20.8%** (90.9% above the low). Trading 21% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.15** (volatility 67%). Beta of 1.15 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EOLS · Page: https://foliofundamentals.com/stocks/eols

Not investment advice.